Short Interest in Lantheus Holdings, Inc. (NASDAQ:LNTH) Drops By 18.3%

Lantheus Holdings, Inc. (NASDAQ:LNTH) saw a large drop in short interest in July. As of July 31st, there was short interest totalling 3,740,000 shares, a drop of 18.3% from the July 15th total of 4,580,000 shares. Based on an average daily volume of 1,070,000 shares, the days-to-cover ratio is presently 3.5 days.

Lantheus Trading Down 0.2 %

Shares of Lantheus stock traded down $0.19 during trading on Friday, hitting $94.91. 488,780 shares of the company were exchanged, compared to its average volume of 1,062,541. The firm has a market capitalization of $6.58 billion, a P/E ratio of 14.49 and a beta of 0.51. The firm’s fifty day moving average price is $95.35 and its 200 day moving average price is $76.27. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.55. Lantheus has a 1-year low of $50.20 and a 1-year high of $126.89.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing the consensus estimate of $1.68 by ($0.07). The firm had revenue of $394.10 million during the quarter, compared to the consensus estimate of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The firm’s revenue for the quarter was up 22.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.40 EPS. As a group, sell-side analysts expect that Lantheus will post 6.46 earnings per share for the current fiscal year.

Insider Transactions at Lantheus

In other news, CAO Andrea Sabens sold 341 shares of the stock in a transaction on Thursday, June 13th. The shares were sold at an average price of $79.77, for a total value of $27,201.57. Following the completion of the transaction, the chief accounting officer now owns 62,557 shares in the company, valued at approximately $4,990,171.89. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, CAO Andrea Sabens sold 341 shares of the business’s stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $79.77, for a total value of $27,201.57. Following the sale, the chief accounting officer now owns 62,557 shares of the company’s stock, valued at approximately $4,990,171.89. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, President Paul Blanchfield sold 2,000 shares of the stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the transaction, the president now owns 98,980 shares of the company’s stock, valued at $9,540,682.20. The disclosure for this sale can be found here. In the last quarter, insiders have sold 72,439 shares of company stock valued at $6,432,198. 1.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Farallon Capital Management LLC increased its position in shares of Lantheus by 595.3% during the first quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider’s stock worth $92,316,000 after acquiring an additional 1,269,900 shares in the last quarter. Norges Bank acquired a new stake in shares of Lantheus in the 4th quarter valued at about $29,956,000. Swedbank AB bought a new stake in shares of Lantheus in the first quarter valued at about $26,346,000. Nomura Holdings Inc. lifted its holdings in shares of Lantheus by 105.3% in the fourth quarter. Nomura Holdings Inc. now owns 20,678 shares of the medical equipment provider’s stock valued at $1,282,000 after purchasing an additional 407,507 shares in the last quarter. Finally, Westfield Capital Management Co. LP boosted its position in shares of Lantheus by 25.3% during the first quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider’s stock worth $121,867,000 after buying an additional 394,837 shares during the period. 99.06% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently issued reports on LNTH. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. Truist Financial lowered their price target on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a report on Thursday, August 1st. B. Riley boosted their price objective on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. JMP Securities decreased their price objective on Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 1st. Finally, SVB Leerink boosted their target price on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, July 11th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $119.00.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.